Prevalence and Healthcare Consumption of ASD Patients Using French Medico-administrative Data (ECO-TSA)

Prevalence and Healthcare Consumption of ASD Patients Using French Medico-administrative Data (SNDS)

Autism Spectrum Disorder (ASD) is one of the neurodevelopmental disorders described in the DSM5 (American Psychiatric Association, 2013). This heterogeneous syndrome appears in childhood and persists throughout life with different developments from one individual to another. It is clinically characterized by the combination of deficits in social communication with restricted and repetitive behaviors. The prevalence of ASD has seen a significant increase over the last 10 years, with estimates varying greatly from one country to another, ranging from 4.2/1,000 in France to 31/1,000 in Iceland. In France, prevalence has been estimated by two child disability registers set up in the departments of Haute-Garonne (RHE31), Isère, Savoie, and Haute-Savoie (RHEOP), but there is no epidemiological surveillance system to estimate the national prevalence of ASD in the general population. However, the production of reliable epidemiological data at the national and territorial levels is essential for addressing the needs of individuals with ASD and for evaluating public policies.

The main objective of our project is to estimate the annual prevalence of ASD in children, adolescents, and young adults at the national and regional levels using medico-administrative databases (SNDS), to study its evolution over the period 2010-2019 and its geographical distribution in relation to socio-demographic indicators and healthcare accessibility. Our secondary objectives are to validate an algorithm for detecting ASD in the National Health Data System (SNDS) and to estimate the direct medical costs associated with ASD management.

The SNDS databases contain all medical care and treatments reimbursed for Health Insurance beneficiaries provided in the private or public sector. A case detection algorithm will be tested and validated on validation samples. Then, the prevalence of ASD will be estimated, taking into account geographical, socio-economic, and healthcare accessibility indicators, in order to study the factors associated with the significant disparity in rates observed in France and abroad. An estimate of direct medical costs will be made from the health insurance perspective.

Our project therefore proposes the development of reliable indicators on the management of ASD in France with the aim of providing useful indicators and tools for guiding health and disability policies in France, promoting the development of appropriate interventions, and thus contributing to the improvement of the care and support of individuals with ASD as well as reducing inequalities in access to healthcare for these vulnerable populations.

Study Overview

• Status: Recruiting
• Conditions: Autism Spectrum Disorder

• Study Type: Observational
• Enrollment (Estimated): 600

Contacts and Locations

Study Locations

• France
  • Dijon, France
    • Not yet recruiting
    • University Hospital Dijon
    • Principal Investigator: Catherine Quantin, Prof.
  • Montpellier, France, 34295
    • Recruiting
    • University Hospital Montpellier
    • Contact: Amaria Baghdadli, Prof; Phone Number: +33467339864; Email: rech-clinique-autisme@chu-montpellier.fr
    • Contact: Julie Loubersac, PhD; Phone Number: +33467339864; Email: j-loubersac@chu-montpellier.fr
    • Principal Investigator: Amaria Baghdadli, Prof
    • Sub-Investigator: Marie-Christine Picot, MD-PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

Population Study are children aged 16 or younger with ASD hospitalized in unversity hospital.

Description

Inclusion Criteria:

• Children aged 16 years or younger
• For case : with an ICD-10 code for ASD (F84*)
• For control : without an ICD-10 code for ASD (F84*)

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ASD diagnostic code in healthcare database	≥ 1 hospitalization with ASD diagnostic code (F84*)	1 year

Secondary Outcome Measures

Outcome Measure	Time Frame
Prevalence of ASD	2010-2019
Cost of medical care reimbursed by health insurance for patient with ASD	2010-2019

Collaborators and Investigators

• Sponsor: University Hospital, Montpellier

Study record dates

Study Major Dates

• Study Start (Estimated): June 1, 2024
• Primary Completion (Estimated): January 1, 2025
• Study Completion (Estimated): January 1, 2025

Study Registration Dates

• First Submitted: May 7, 2024
• First Submitted That Met QC Criteria: May 7, 2024
• First Posted (Estimated): May 10, 2024

Study Record Updates

• Last Update Posted (Estimated): May 10, 2024
• Last Update Submitted That Met QC Criteria: May 7, 2024
• Last Verified: May 1, 2024

More Information

Terms related to this study

• Keywords: Population surveillance; Administrative claims
• Additional Relevant MeSH Terms: Mental Disorders; Neurodevelopmental Disorders; Child Development Disorders, Pervasive; Autism Spectrum Disorder
• Other Study ID Numbers: RECHMPL21_0063

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No